With over 15 years experience providing recombinant protein production services, we have acquired a solid know-how and are able to design solutions for even the most challenging proteins
When the company started off, over 15 years ago, GTP was one of the very few private organisations to offer custom services for recombinant protein production. Since then, we have expressed over 800 different proteins - most often challenging – and developed a unique mix of protein science and process expertise. GTP is well placed to help transition your projects from early discovery through to transfer to manufacturing.
Our team, composed of dedicated and dynamic scientists is driven by a desire to continuously improve the quality of our protein expression services. Our facilities host the appropriate equipment to support the development of bioprocesses with multiple expression systems for a wide range of proteins and applications.
We are also working with a set of partners to provide advanced and integrated solutions for the success of your recombinant protein projects.
With over 400 diverse recombinant proteins successfully expressed in Escherichia coli, multiple process developments and transfers to GMP facilities, GTP’s experience will help overcome your E. coli expression challenges.
Escherichia coli is the expression platform in 40% of our projects
Because its genetics are understood more than those of any other microorganism and because of its high yields combined with low production costs, Escherichia coli is the most widely used host for recombinant protein expression.
Whether it is for the development of a therapeutic or a vaccine, or the production of a reagent for research studies or diagnostics development, we always consider E. coli as a first choice.
An exception is for the expression of complex proteins that require post-translational modifications, where systems such as mammalian cells, insect cells or yeasts are preferred.
We offer our expertise in protein expression and process development with E. coli
For the successful production of your recombinant protein in E. coli, we offer customised services that include:
We have successfully expressed a variety of recombinant proteins, monoclonal antibodies and antibody fragments in mammalian systems.
Mammalian cells are in most cases the optimal system to produce recombinant mammalian proteins, because of their capacity for proper protein folding, post-translational modifications, and protein assembly, which are important for complete biological activity.
In the last decade, the increase in large molecule therapeutic development has resulted in the emergence of more cost-effective and efficient mammalian systems. CHO is currently the main host for commercial production of therapeutic proteins, including monoclonal antibody (mAbs).
We offer a comprehensive range of services for the expression of your protein in a mammalian system
For the successful production of your protein or antibody in mammalian cells, we offer a comprehensive range of services including:
For early activity studies, we have developed an efficient transient transfection platform in either CHO or HEK cells allowing the production of antibody quantities ranging from micrograms to grams. With our optimised expression conditions, we routinely achieve high expression yields for a variety of human and mouse antibodies.
For early stages of process development, we offer, through our partnerships with technology companies, CHO cell line development and banking (Research and Master Cell Bank) services. Depending on your requirements and constraints, we will opt for IP-free or proprietary technologies to develop high-titer mammalian cell lines.
We have successfully expressed over 200 different proteins in insect cells
The popularity of the insect cells-baculovirus system comes from its ability to produce relatively large quantities of post-translationally modified eukaryotic proteins in a relatively short period of time and with competitive production costs.
Since the system is lytic, it is suited for both intracellular and secreted proteins, and is ideal for those with inhibitory or toxic effects on mammalian host cells.
For this reason, it has been largely used for the production of a variety of target proteins. But this lytic feature is a limitation for industrial production, for which mammalian cells are still largely preferred, particularly for therapeutic projects.
For very challenging cases, when exploring the potential of insect cells for large scale production is necessary, GTP has perfectly suited expertise and capabilities.
We offer a comprehensive range of services for the expression of your protein in insect cells
For successful production in insect cells, we offer a comprehensive range of services including:
Depending on your project stage, your objectives and your IP constraints, we will suggest the insect cells-baculovirus technologies best suited to your needs.
Based on our experience over hundreds of projects, we know how crucial it is for the expression of challenging recombinant proteins and antibodies to design optimised genes and constructs.
Our scientists have a strong background in molecular biology on which we have drawn over time to develop tricks and tools to increase the expression.
We have developed our own gene optimisation tool (see our blog article “How to make gene optimisation for expression in Escherichia coli a piece of cake”) which takes into account parameters that are usually left aside by gene synthesis companies (such as mRNA secondary structure in the translational initiation and slippage-prone sequences). We use this tool on each project where synthesis is required.
We also offer a set of commercial vectors as well as our own customised vectors, for each classical expression systems.
For E. coli for example, we have developed four IP-free vectors with different features, all designed to improve protein expression and stability. For projects with an industrial application, we will most often suggest the use of these vectors.
For projects that require specific construct design, we are pleased to offer consultancy services to help you develop the most efficient system for your challenging protein.
We offer customised process development services to meet your quality and time objectives
We have supported over 20 microbial process development programs, delivering either processes for decagram batches such as for preclinical studies, or a robust and scalable process for transfer to a GMP facility.
Be it for E. coli or P. pastoris systems, our focus is on developing high-expressing strains and identifying the optimal expression conditions for high titer and critical quality attributes while ensuring process robustness and scalability.
With the nature of your protein and your IP constraints in mind, we will suggest the appropriate expression platform. For E. coli, our optimised IP-free vectors, designed for improved protein expression and stability, are, most of the time, the best option.
For very challenging protein, when traditional E. coli systems have failed, we offer to evaluate innovative E. coli strains through our partnerships with research platforms and technology companies.
Our experienced team will deliver a robust, efficient and scalable upstream process, ready to transfer
We offer a comprehensive set of process development services to deliver GMP ready upstream processes:
Our fermentation facilities host the appropriate equipment for each development stage, from 2 to 5L glass fermenters for process optimisation, to 50L stainless steel fermenters for pilot production. The methods and platforms used are among the standards of most CMOs, for a cost-effective and seamless transfer to the cGMP manufacturing suite of your choice.
Biochemistry & Molecular Biology Services
Recombinant Protein Expression Services
GTP Technology has not received any reviews.
GTP Technology has not received any endorsements.